QNTM (Quantum BioPharma) Debt-to-EBITDA : -0.02 (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Quantum BioPharma Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Quantum BioPharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.37 Mil. Quantum BioPharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. Quantum BioPharma's annualized EBITDA for the quarter that ended in Sep. 2024 was $-15.54 Mil. Quantum BioPharma's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was -0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Quantum BioPharma's Debt-to-EBITDA or its related term are showing as below:

QNTM' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.46 Med: -0.02 Max: -0.02
Current: -0.04

During the past 9 years, the highest Debt-to-EBITDA Ratio of Quantum BioPharma was -0.02. The lowest was -1.46. And the median was -0.02.

QNTM's Debt-to-EBITDA is ranked worse than
100% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs QNTM: -0.04

Quantum BioPharma Debt-to-EBITDA Historical Data

The historical data trend for Quantum BioPharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantum BioPharma Debt-to-EBITDA Chart

Quantum BioPharma Annual Data

Trend

Aug15

Aug16

Aug17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.05

-0.02

Quantum BioPharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.03	-0.06	-0.08	-0.05	-0.02

Competitive Comparison of Quantum BioPharma's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Quantum BioPharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quantum BioPharma's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Quantum BioPharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Quantum BioPharma's Debt-to-EBITDA falls into.

Quantum BioPharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Quantum BioPharma's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.339	+	0)	/	-15.724
	=	-0.02

Quantum BioPharma's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.373	+	0)	/	-15.536
	=	-0.02

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.

Quantum BioPharma (NAS:QNTM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Quantum BioPharma Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Quantum BioPharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Quantum BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Quantum BioPharma Ltd (NAS:QNTM) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

0K91:Germany QNTM:Canada

Address

199 Bay Street, Suite 4000, Toronto, ON, CAN, M5L 1A9

Website

https://www.fsdpharma.com

Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.